Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
10 May 1991Website:
http://www.haemonetics.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 1 min agoDividend
Analysts recommendations
Institutional Ownership
HAE Latest News
Donidalorsen will be a first-in-class RNA-targeted medicine for hereditary angioedema, assuming approval Donidalorsen PDUFA date set for August 21, 2025 Donidalorsen has the potential to be Ionis' second independent commercial launch CARLSBAD, Calif. , Nov. 4, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week primary observation period. Despite the stock price trading lower by 20%, the HAE treatment program continues on using NTLA-2002 in the phase 3 HAELO study. The global hereditary angioedema treatment market size is projected to reach $17.31 billion by the end of 2032.
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema (HAE), with results continuing to indicate that NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for HAE, a rare genetic condition that leads to potentially life-threatening swelling attacks. Results were published online today in The New England Journal of Medicine and will be presented on Saturday, October 26 at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Scientific Meeting in Boston, Massachusetts.
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
HAE's hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
BOSTON , Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024.
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks.
What type of business is Haemonetics?
Haemonetics Corporation is a global provider of products and services for blood and plasma transfusion. The company was founded in Braintree, Massachusetts in 1971 by Dr. Jack Latham. Initially, the company focused on manufacturing containers and bags for blood collection. Now, the company's main products include: - Donor products - These include automation tools for blood collection and analysis, devices for detecting bacteria and pathogens in blood, and hematocrit testing. - Products for stopping blood loss in patients - These are surgical devices for blood conservation, blood aspiration systems, and blood warming devices.
What sector is Haemonetics in?
Haemonetics is in the Healthcare sector
What industry is Haemonetics in?
Haemonetics is in the Medical Instruments & Supplies industry
What country is Haemonetics from?
Haemonetics is headquartered in United States
When did Haemonetics go public?
Haemonetics initial public offering (IPO) was on 10 May 1991
What is Haemonetics website?
https://www.haemonetics.com
Is Haemonetics in the S&P 500?
No, Haemonetics is not included in the S&P 500 index
Is Haemonetics in the NASDAQ 100?
No, Haemonetics is not included in the NASDAQ 100 index
Is Haemonetics in the Dow Jones?
No, Haemonetics is not included in the Dow Jones index
When was Haemonetics the previous earnings report?
No data
When does Haemonetics earnings report?
The next expected earnings date for Haemonetics is 07 November 2024